Health system pharmacists ready for BTC medications

January 2008
Drug Formulary Review;Jan2008, Vol. 24 Issue 1, p5
The article deals with the testimony of William Zellmer, the deputy executive vice president of the American Society of Health System Pharmacists, at a hearing of the U.S. Food and Drug Administration about the proposal to expand the role of pharmacists in patient care and medical therapy. Zellmer relates the increase of outpatient pharmacy in hospitals. Zellmer claims that behind-the-counter availability of certain medications would be in the public interest. He relates the features of a pharmacist's practice when providing these therapies.


Related Articles

  • Clarify pedigree: NWDA.  // Drug Topics;5/23/94, Vol. 138 Issue 10, p64 

    Reports on the National Wholesale Druggists' Association's criticisms against the Food and Drug Administration's proposal on drug pedigree for the Prescription Drug Marketing Act.

  • GAO says FDA can do more to stop drug shortages. Lee, Jaimy // Modern Healthcare;2/10/2014, p0004 

    The article reports on the remarks of the U.S. Government Accountability Office (GAO) to the Food and Drug Administration (FDA) regarding its steps to stop the drug shortages in the U.S. Topics discussed include the healthcare in the U.S., the patient care, and the hospital operations. Also...

  • FDA Notice to Halt Morphine Production Causes Concern.  // Journal of Gerontological Nursing;Jul2009, Vol. 35 Issue 7, p35 

    The article reports that the American Society of Consultant Pharmacists (ASCP) calls for remedial action after the U.S. Food and Drug Administration's (FDA) notice to halt the manufacturing of morphine sulphate 20 mg/mL oral concentrate was disapproved. The ASCP has cited the shortage of...

  • News Briefs.  // American Journal of Health-System Pharmacy;11/15/2006, Vol. 63 Issue 22, p2180 

    The article offers news briefs in the U.S. The Canadian Society of Hospital Pharmacists has adopted Comprehensive School Health Program 2015. The Food and Drug Administration approved the marketing of 4% icodextrin adhesion reduction solution indicated as a medical device for intraperitoneal...

  • ASHP Statement on Bar-Code-Enabled Medication Administration Technology.  // Best Practices for Hospital & Health-System Pharmacy;2014/2015, p6 

    The article focuses on the effort of the organization American Society of Health-System Pharmacists (ASHP) to encourage health systems to adopt bar-code enabled medication administration (BCMA) technology to improve patient safety and accuracy in medication administration. It offers overview of...

  • New options for patients with allergies, overactive bladders. TANZI, MARIA G. // Pharmacy Today;Feb2014 OTC Supplement, p4 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) of two over-the-counter drugs for patients with allergies and overactive bladders, the triamcinolone acetonide nasal spray and oxybutynin transdermal system. It looks at the concerns of FDA Nonprescription Drugs...

  • OTC lovastatin hits barrier. Price, Suzanne // Pharmacy Today;Feb2005, Vol. 11 Issue 2, p19 

    The article reports that the U.S. Food and Drug Administration's Nonprescription Drugs and Endocrinologic and Metabolic Drugs Advisory Committees voted against recommending that the agency allow OTC sales of lovastatin 20 mg. Committee members agreed that the drug was effective in lowering...

  • Patient-Centered Product Substitution Decision Support Tool for Pharmacists.  // Journal of the American Pharmacists Association: JAPhA;May/Jun2007, Vol. 47 Issue 3, p332 

    The article presents a patient-centered product substitution decision support tool for pharmacists. It cites the information needed by pharmacists from patients to factor into product substitution decision. Pharmacists should evaluate the clinical significance of the potential variability when...

  • Look-alike, sound-alike drug errors with Reminyl and Amaryl. Reines, Scott A. // American Journal of Health-System Pharmacy;1/1/2005, Vol. 62 Issue 1, p35 

    This article focuses on drug errors with Reminyl and Amaryl. According to reports spontaneously submitted to Food and Drug Administration and the U.S. Pharmacopeia, the confusion between Reminyl and Amaryl stems from the similarity in trade names, the availability of both as 4-mg tablets, and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics